Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biomark DiagnosticsSTU:20B 27 OCF Margin % is -1,900.00% as of Mar. 2026. GuruFocus rates STU:20B with a GF Score™ of 27/100. The stock has 4 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Biomark Diagnostics ranks worse than 95.57% on this metric.
The historical rank and industry rank for Biomark Diagnostics's OCF Margin % or its related term are showing as below:
STU:20B'
s OCF Margin % Range Over the Past 10 Years
Min: -2736.36 Med: -656.41 Max: -172.62
Current: -1835.14
During the past 13 years, the highest OCF Margin % of Biomark Diagnostics was -172.62%. The lowest was -2736.36%. And the median was -656.41%.
STU:20B's OCF Margin % is ranked worse than 95.57% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: 5.4
vs STU:20B: -1835.14
The historical data trend for Biomark Diagnostics's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:20B vs TMO, DHR, IDXX: OCF Margin % Comparison
For the Diagnostics & Research subindustry, Biomark Diagnostics's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomark Diagnostics OCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biomark Diagnostics's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Biomark Diagnostics's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomark Diagnostics (STU:20B) has a OCF Margin % of -1,900.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Biomark Diagnostics and its competitors. According to the industry distribution chart, Biomark Diagnostics ranks #194 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 95.6%.
Is Biomark Diagnostics' OCF Margin % too high?
Biomark Diagnostics' current OCF Margin % is -1,900.00%. Based on the distribution chart, Biomark Diagnostics ranks #194 out of 203 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Biomark Diagnostics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Biomark Diagnostics' OCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Biomark Diagnostics ranks #194 out of 203 companies for OCF Margin %. This places Biomark Diagnostics in the lower half of its industry. The industry median OCF Margin % is 5.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Diagnostics & Research company?
The median OCF Margin % among Medical Diagnostics & Research companies is 5.40, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Biomark Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median OCF Margin % is 5.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biomark Diagnostics's current OCF Margin % is -1,900.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomark Diagnostics stock overvalued right now?
Biomark Diagnostics (STU:20B) has a current OCF Margin % of -1,900.00%. The current OCF Margin % is -1,900.00%. Biomark Diagnostics' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Biomark Diagnostics (STU:20B), the current OCF Margin % is -1,900.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early cancer treatment. Its research and development are focused on the role that metabolomics plays in early cancer detection. The company's objective is to commercialize its inventive technology. and strive to increase the predictive accuracy in early-stage cancer detection.
27GF Score
Get the complete analysis for STU:20B
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:20B has been successfully added to your 
